Ductus Arteriosus, Patent ; drug therapy ; Humans ; Indomethacin ; therapeutic use ; Infant, Extremely Low Birth Weight ; Infant, Newborn

Humans ; Infant, Newborn ; Neonatal Screening

Administration, Topical ; Aged ; Child ; Cyclopropanes ; administration & dosage ; adverse effects ; Female ; Haptens ; administration & dosage ; adverse effects ; Humans ; Male ; Middle Aged ; Vitiligo ; chemically induced

Cutaneous pseudolymphoma refers to a heterogenous group of benign T-cell or B-cell lymphoproliferative processes that mimic cutaneous lymphoma clinically and sometimes histologically. The causes of cutaneous pseudolymphoma are diverse, including lymphomatoid drug eruptions, lymphomatoid contact dermatitis, arthropod-bite reactions, chronic actinic dermatitis (CAD). Here we describe a case of pseudolymphoma due to hair dye on background of CAD.

Actinomycosis ; complications ; drug therapy ; pathology ; Aged, 80 and over ; Amoxicillin-Potassium Clavulanate Combination ; therapeutic use ; Anti-Bacterial Agents ; therapeutic use ; Cephalexin ; therapeutic use ; Ciprofloxacin ; therapeutic use ; Clindamycin ; therapeutic use ; Coinfection ; drug therapy ; Drug Resistance, Bacterial ; Escherichia coli Infections ; complications ; drug therapy ; Humans ; Male ; Pseudomonas Infections ; complications ; drug therapy ; Skin Diseases, Bacterial ; complications ; drug therapy ; pathology ; Staphylococcal Skin Infections ; complications ; drug therapy ; Thigh ; Trimethoprim, Sulfamethoxazole Drug Combination ; therapeutic use

Developmental dysplasia of the hip (DDH) is an intriguing condition that evolves during infancy. It would be thus foolhardy to expect a screening tool at birth to be both highly sensitive and specific. Uncertainty regarding an optimal screening method is compounded by a general lack of sound epidemiological data. Clinical screening remains widely used. Some reports estimated that it did not pick up 60% of children who eventually needed surgery. Ultrasonography, it was hoped, would improve detection rates. There are 2 approaches to ultrasound; universal screening, which is adopted by some European countries, or selective screening of high risk infants. The problems with universal ultrasound screening are high false positive rates and high costs. The benefit was a possible 6- to 10-fold reduction in surgery for late DDH. Similar reductions though had also been reported if ultrasound was used selectively for infants with clinical and historical risk factors. A literature review on this topic is presented. There are pros and cons for both screening strategies. This is reflected in the different protocols that exist among various countries. For healthcare systems that are considering their options, universal ultrasound screening is generally not cost-effective and should not be the preferred screening strategy.
Hip Dislocation, Congenital ; diagnostic imaging ; Humans ; Infant ; Mass Screening ; statistics & numerical data ; Patient Selection ; Ultrasonography

Anti-Inflammatory Agents ; administration & dosage ; Arthritis ; diagnosis ; drug therapy ; etiology ; physiopathology ; Arthritis, Rheumatoid ; diagnosis ; Clofazimine ; administration & dosage ; Dapsone ; administration & dosage ; Delayed Diagnosis ; Diagnosis, Differential ; Humans ; Leprostatic Agents ; administration & dosage ; Leprosy ; complications ; diagnosis ; drug therapy ; physiopathology ; Male ; Middle Aged ; Prednisolone ; administration & dosage ; Rifampin ; administration & dosage ; Treatment Outcome

INTRODUCTIONTo explore the relationship between ethnic origin and mode of feeding with early neonatal jaundice, we examined maternal and neonatal risk factors for hyperbilirubinaemia in a multi-ethnic Asian cohort of healthy term newborns.

MATERIALS AND METHODSThis is an observational cohort study in a maternity ward serving a multi-ethnic cosmopolitan community. The relationship between hyperbilirubinaemia (bilirubin >or=150 mmol/L before 48 hours to 72 hours after birth), ethnic origin, weight loss after birth, need for phototherapy, and other factors were examined. Bivariate comparisons and binary logistic regression were used to investigate the relationship between hyperbilirubinaemia/phototherapy with maternal and neonatal risk factors.

RESULTSA consecutive group of 1034 neonates (56% Chinese, 24% Indian subcontinent, 9% Malay) with birth weights >or=2500 g was investigated. Overall factors that contributed significantly to hyperbilirubinaemia/phototherapy were gestational age, Chinese ethnic origin, weight loss of >or=7%, vaginal delivery, glucose-6-phosphate-dehydrogenase (G6PD) deficiency, breastfeeding and ABO incompatibility. Chinese neonates who were totally breastfed had a higher risk for jaundice [adjusted odds ratio (OR) = 1.64; 95% confidence intervals (CI), 1.11- 2.44; P <0.014], and phototherapy (adjusted OR = 2.75; 95% CI 1.77-4.27; P <0.001) compared to those supplemented with, or totally formula fed. In contrast, the risk of jaundice for non- Chinese infants did not differ according to the mode of feed. Although weight loss as a whole increased the risk for jaundice (adjusted OR = 1.43; 95%CI, 1.03-1.99; P = 0.031), jaundice in Chinese neonates was not due to ineffective breastfeeding because both Chinese and non-Chinese breastfed infants lost similar weights.

CONCLUSIONSChinese ethnic origin was an independent risk factor for hyperbilirubinaemia and phototherapy. Breastfeeding was not a risk factor for hyperbilirubinaemia/phototherapy in non-Chinese Asian infants.

Asian Continental Ancestry Group ; Breast Feeding ; Ethnic Groups ; Female ; Gestational Age ; Humans ; Hyperbilirubinemia, Neonatal ; etiology ; therapy ; Infant Formula ; Infant, Newborn ; Jaundice, Neonatal ; etiology ; Male ; Phototherapy ; Risk Factors

INTRODUCTION: Proton pump inhibitors (PPIs) are effective treatments for upper gastrointestinal pathologies and short-term courses are well-tolerated. However, indiscriminate use of PPIs is undesirable due to its potential harms. We implemented a series of deprescribing interventions between 2016 and 2017 to curb PPI overutilisation in our institution. The aim of this study was to evaluate the effectiveness and safety of these interventions. METHODS: An institutional PPI deprescribing guide was disseminated by email and educational roadshows were conducted to prescribers. Interrupted time series analysis was used to evaluate the effectiveness of the deprescribing interventions over a 7-year period from 2013 to 2019. To ascertain the safety of PPI deprescribing, we analysed the peptic ulcer disease incidence from 2015 to 2018 and conducted a retrospective chart review of 262 inpatients who were deprescribed PPIs. RESULTS: Following the first intervention, there was a significant decrease in mean oral PPI utilisation by 2,324.46 defined daily doses (DDD) per 1,000 prescriptions (95% confidence interval [CI] -3,542.66, -1,106.26) per month, followed by a month-to-month decrease of 302.61 DDD per 1,000 prescriptions per month thereafter (95% CI -473.95, -131.27). A second targeted educational intervention was only effective in sustaining the decline in the outpatient, but not in the inpatient setting. There were no significant changes in incidence of peptic ulcer disease. In the retrospective chart review, a majority (62.6%) of patients remained deprescribed at 6 months. CONCLUSION We observed a sustained decrease in PPI utilisation in our institution for more than 12 months following our educational interventions. Cautious deprescribing of PPIs in eligible candidates was found to be safe with low recurrence rates of upper gastrointestinal events.
Deprescriptions ; Humans ; Proton Pump Inhibitors ; Quality Improvement ; Retrospective Studies ; Singapore/epidemiology* ; Tertiary Care Centers